Citations

Showing 10 of 108162 citations.

Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis
Schulte, Jefree J. , Chapel, David B. , Attanoos, Richard , Brčić, Luka , Burn, Juliet, Butnor, Kelly J. , Chang, Nina, Chen, Heather , Đačić, Sanja , Godschachner, Theresa, Hiroshima, Kenzo , Klebe, Sonja , Krausz, Thomas, Litzky, Leslie A., Marchevsky, Alberto M. , Mueller, Jeffrey , Nabeshima, Kazuki , Roden, Anja C. , Rørvig, Sara, Santoni‐Rugiu, Eric , Tazelaar, Henry D. , Walts, Ann E. , Weynand, Birgit , Zaizen, Yoshiaki , Zhang, Yu Zhi , Husain, Aliya N. , Santoni-Rugiu, Eric , Tazelaar, Henry, Zhang, Yu Zhi , Zaizen, Yoshiaki , de Perrot, Marc , Fukuoka, Junya , Galateau-Sallé, Françoise , Nicholson, Andrew G. , Pal, Prodipto , Tazelaar, Henry D. , Tsao, Ming‐Sound

Mayo Clinic

American Journal of Clinical Pathology | March 16, 2021 | Volume: 156 | Issue: 6 | Pages: 989-999

10.1093/ajcp/aqab054 | PMID 33978147 Get It

Abstract Objectives Numerous studies on malignant mesothelioma (MM) highlight the prognostic importance of histologic subtype, nuclear grade, and necrosis. This study compares these parameters in paired biopsy and resection specimens of pleural MM. Methods Histologic subtype, percentage of epithelioid morphology, nuclear grade, and the presence or absence of necrosis were compared in 429 paired biopsies and resection specimens of pleural MM from 19 institutions. Results Histologic subtype was concordant in 81% of cases (κ = 0.58). When compared with resection specimens, epithelioid morphology at biopsy had a positive predictive value (PPV) of 78.9% and a negative predictive value (NPV) of 93.5%; sarcomatoid morphology showed high PPV (92.9%) and NPV (99.3%), and biphasic morphology PPV was 89.7% and NPV was 79.7%. Agreement of the percentage of epithelioid morphology was fair (κ = 0.27). Nuclear grade and necrosis were concordant in 75% (κ = 0.59) and 81% (κ = 0.53) of cases, respectively. Nuclear grade showed moderate (κ = 0.53) and substantial (κ = 0.67) agreement from patients with and without neoadjuvant therapy, respectively, and necrosis showed moderate (κ = 0.47 and κ = 0.60) agreement, respectively, in the same subsets of paired specimens. Conclusions Paired biopsy-resection specimens from pleural MM show overall moderate agreement in pathologic parameters. These findings may help guide postbiopsy management and triage of patients with MM.
Non-Coding RNAs in Hereditary Kidney Disorders
Zhou, Julie , Li, Xiaogang

Mayo Clinic

International Journal of Molecular Sciences | March 16, 2021 | Volume: 22 | Issue: 6 | Pages: 3014

10.3390/ijms22063014 | PMID 33809516 Get It

Single-gene defects have been revealed to be the etiologies of many kidney diseases with the recent advances in molecular genetics. Autosomal dominant polycystic kidney disease (ADPKD), as one of the most common inherited kidney diseases, is caused by mutations of PKD1 or PKD2 gene. Due to the complexity of pathophysiology of cyst formation and progression, limited therapeutic options are available. The roles of noncoding RNAs in development and disease have gained widespread attention in recent years. In particular, microRNAs in promoting PKD progression have been highlighted. The dysregulated microRNAs modulate cyst growth through suppressing the expression of PKD genes and regulating cystic renal epithelial cell proliferation, mitochondrial metabolism, apoptosis and autophagy. The antagonists of microRNAs have emerged as potential therapeutic drugs for the treatment of ADPKD. In addition, studies have also focused on microRNAs as potential biomarkers for ADPKD and other common hereditary kidney diseases, including HNF1β-associated kidney disease, Alport syndrome, congenital abnormalities of the kidney and urinary tract (CAKUT), von Hippel–Lindau (VHL) disease, and Fabry disease. This review assembles the current understanding of the non-coding RNAs, including microRNAs and long noncoding RNAs, in polycystic kidney disease and these common monogenic kidney diseases.
Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences
Koziorowski, Dariusz , Figura, Monika , Milanowski, Łukasz , Alster, Piotr , Madetko‐Alster, Natalia , Friedman, Andrzej , Milanowski, Łukasz M , Alster, Piotr , Koziorowski, Dariusz , Szlufik, Stanisław

Mayo Clinic

Cells | March 16, 2021 | Volume: 10 | Issue: 3 | Pages: 656

10.3390/cells10030656 | PMID 33809527 Get It

Parkinson’s disease (PD), dementia with Lewy body (DLB), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) belong to a group of neurodegenerative diseases called parkinsonian syndromes. They share several clinical, neuropathological and genetic features. Neurodegenerative diseases are characterized by the progressive dysfunction of specific populations of neurons, determining clinical presentation. Neuronal loss is associated with extra- and intracellular accumulation of misfolded proteins. The parkinsonian diseases affect distinct areas of the brain. PD and MSA belong to a group of synucleinopathies that are characterized by the presence of fibrillary aggregates of α-synuclein protein in the cytoplasm of selected populations of neurons and glial cells. PSP is a tauopathy associated with the pathological aggregation of the microtubule associated tau protein. Although PD is common in the world’s aging population and has been extensively studied, the exact mechanisms of the neurodegeneration are still not fully understood. Growing evidence indicates that parkinsonian disorders to some extent share a genetic background, with two key components identified so far: the microtubule associated tau protein gene (MAPT) and the α-synuclein gene (SNCA). The main pathways of parkinsonian neurodegeneration described in the literature are the protein and mitochondrial pathways. The factors that lead to neurodegeneration are primarily environmental toxins, inflammatory factors, oxidative stress and traumatic brain injury.
Bioadhesives: A Multifunctional Origami Patch for Minimally Invasive Tissue Sealing (Adv. Mater. 11/2021)
Yuk, Hyunwoo , Wu, Sarah Jinhui , Wu, Jingjing , Nabzdyk, Christoph S. , Zhao, Xuanhe

Mayo Clinic

Advanced Materials | March 16, 2021 | Volume: 33 | Issue: 11 | Pages: No page available

10.1002/adma.202170083 Get It

Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging
Syrjanen, Jeremy A. , Christianson, Teresa J., Kremers, Walter K. , Petersen, Ronald C. , Vassilaki, Maria , Geda, Yonas E. , Krell-Roesch, Janina, Geda, Yonas E , Kremers, Walter K , Krell‐Roesch, Janina , Machulda, Mary M. , Mielke, Michelle M. , Knopman, David S.

Mayo Clinic

International Journal of Geriatric Psychiatry | March 16, 2021 | Volume: 36 | Issue: 9 | Pages: 1362-1369

10.1002/gps.5528 | PMID 33724517 Get It

Abstract Objective Neuropsychiatric symptoms (NPS) are associated with the risk of incident mild cognitive impairment (MCI) and dementia. We examined associations between NPS and the outcomes of global and domain‐specific cognitive trajectories. Methods In this longitudinal study conducted in the setting of the population‐based Mayo Clinic Study of Aging, 5081 community‐dwelling, nondemented individuals aged ≥50 years (51% males) underwent NPS assessment using Neuropsychiatric Inventory Questionnaire (NPI‐Q), and Beck Depression and Anxiety Inventories (BDI‐II, BAI). Global and domain‐specific (memory, language, attention, and visuospatial skills) cognitive performance was assessed through neuropsychological testing every 15 months. Associations between baseline NPS and trajectories for individual yearly change in cognitive z‐scores were calculated using linear mixed‐effect models. Results Cognition declined regardless of NPS status over the median follow‐up of 4.5 years. Presence of NPS was associated with increased cognitive decline. Differences in annualized change in global cognition z‐scores for participants with NPS compared to without NPS ranged from −0.018 (95% CI −0.032, −0.004; p = 0.011) for irritability to −0.159 (−0.254, −0.065; p = 0.001) for hallucinations. Associations between NPS and annual decline in global cognition were significant for most NPI‐Q‐assessed NPS and clinical depression (BDI‐II≥13). Participants with NPI‐Q‐assessed depression, apathy, nighttime behavior, and clinical depression had greater decline in all domain‐specific z‐scores; presence of delusions and anxiety was associated with more pronounced decline in language, attention and visuospatial skills. Conclusion NPS were associated with a more accelerated cognitive decline. Clinical assessment and potential treatment of NPS is warranted even in a community setting as NPS may impact cognitive decline in nondemented individuals.
Survival of Ventilated Extremely Premature Neonates With Severe Intraventricular Hemorrhage
McCauley, Kortany, Carey, Elise C. , Weaver, Amy L. , Mara, Kristin C. , Carey, William A., Collura, Christopher A. , Mara, Kristin C , Clark, Reese H.

Mayo Clinic

Pediatrics | March 16, 2021 | Volume: 147 | Issue: 4 | Pages: No page available

10.1542/peds.2020-1584 | PMID 33727247 Get It

BACKGROUND: Severe intraventricular hemorrhage (IVH) is a leading mortality risk factor among extremely premature neonates. Because other life-threatening conditions also occur in this population, it is unclear whether severe IVH is independently associated with death. The existence and potential implications of regional variation in severe IVH–associated mortality are unknown. METHODS: We performed a retrospective cohort study of mechanically ventilated neonates born at 22 to 29 weeks’ gestation who received care in 242 American NICUs between 2000 and 2014. After building groups composed of propensity score–matched and center-matched pairs, we used the Cox proportional hazards analysis to test our hypothesis that severe IVH would be associated with greater all-cause in-hospital mortality, defined as death before transfer or discharge. We also performed propensity score–matched subgroup analyses, comparing severe IVH–associated mortality among 4 geographic regions of the United States. RESULTS: In our analysis cohort, we identified 4679 patients with severe IVH. Among 2848 matched pairs, those with severe IVH were more likely to die compared with those without severe IVH (hazard ratio 2.79; 95% confidence interval 2.49–3.11). Among 1527 matched pairs still hospitalized at 30 days, severe IVH was associated with greater risk of death (hazard ratio 2.03; 95% confidence interval 1.47–2.80). Mortality associated with severe IVH varied substantially between geographic regions. CONCLUSIONS: The early diagnosis of severe IVH is independently associated with all-cause in-hospital mortality in extremely premature neonates. Regional variation in severe IVH–associated mortality suggests that shared decision-making between parents and neonatologists is strongly influenced by ultrasound-based IVH assessment and classification.
Prenatal Genetic Diagnosis of a Sex Chromosome Aneuploidy: Parent Experiences
Riggan, Kirsten A. , Gross, Brianna , Close, Sharron , Weinberg, Abigail , Allyse, Megan , Allyse, Megan A , Riggan, Kirsten A

Mayo Clinic

Journal of Genetic Counseling | March 16, 2021 | Volume: 30 | Issue: 5 | Pages: 1407-1417

10.1002/jgc4.1407 | PMID 33723878 Get It

AbstractSex chromosome aneuploidies (SCAs) occur in 1 in every 400 births. SCAs are highly variable and have uncertain prognoses, complicating the delivery of prenatal cell‐free DNA (cfDNA) results or diagnosis following amniocentesis or chorionic villus sampling. Using a mixed‐methods approach, we explored the experiences of parents receiving a prenatal diagnosis of a fetus with SCA. Responses to open‐ended questions were qualitatively analyzed. Of the 323 parents who completed the survey, 122 received a prenatal diagnosis and answered at least one open‐ended question. Most parents did not recall being informed that cfDNA screening or amniocentesis could reveal the presence of a SCA prior to testing and described feeling unprepared for a positive result. Variation was found between parents who were delivered a diagnosis by a genetic professional versus other clinical specialties. Many parents expressed that the diagnosis was delivered in a way that emphasized the negative attributes of the SCA and that they were provided limited support materials. Parents who received a prenatal diagnosis of a SCA expressed a desire for more supportive delivery of prenatal diagnosis that focuses on parental education and nuanced discussion of potential phenotypes. Genetic counselors should be aware of the range of parental experiences when receiving a SCA diagnosis from non‐genetic providers. Prenatal SCA diagnoses are predicted to increase as prenatal cfDNA screening becomes more widely used. Collaborations for greater provider education and comprehensive materials on SCAs are essential to facilitate the delivery of SCA diagnoses and improve parent understanding and support.
AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories
Zhang, Y Victoria , Wiencek, Joesph R , Theel, Elitza S. , Babić, Nikolina , Sepiashvili, Lusia, Pecora, Nicole , Slev, Patricia, Cameron, Andrew , Konforte, Danijela , Wiencek, Joesph , Zhang, Y Victoria, Meng, Qing H.

Mayo Clinic

Clinical Chemistry | March 16, 2021 | Volume: 67 | Issue: 9 | Pages: 1188-1200

10.1093/clinchem/hvab051 | PMID 34470034 Get It

Abstract Background The clinical laboratory continues to play a critical role in managing the coronavirus pandemic. Numerous US Food and Drug Administration emergency use authorization (EUA) and laboratory-developed test (LDT) serologic assays have become available. The performance characteristics of these assays and their clinical utility continue to be defined in real time during this pandemic. The AACC convened a panel of experts from clinical chemistry, microbiology, and immunology laboratories; the in vitro diagnostics industry; and regulatory agencies to provide practical recommendations for implementation and interpretation of these serologic tests in clinical laboratories. Content The currently available EUA serologic tests and platforms, information on assay design, antibody classes including neutralizing antibodies, and the humoral immune responses to SARS-CoV-2 are discussed. Verification and validation of EUA and LDT assays are described, along with a quality management approach. Four indications for serologic testing are outlined. Recommendations for result interpretation, reporting comments, and the role of orthogonal testing are also presented. Summary This document aims to provide a comprehensive reference for laboratory professionals and healthcare workers to appropriately implement SARS-CoV-2 serologic assays in the clinical laboratory and to interpret test results during this pandemic. Given the more frequent occurrence of outbreaks associated with either vector-borne or respiratory pathogens, this document will be a useful resource in planning for similar scenarios in the future.
What do we know about the diagnosis and management of mirror syndrome?
Trad, Ayssa Teles Abrão , Czeresnia, Ricardo Mamber , Elrefaei, Amro , Teles Abrao Trad, Ayssa, Czeresnia, Ricardo, Narang, Kavita , Ibirogba, Eniola R. , Ruano, Rodrigo

Mayo Clinic

The Journal of Maternal-Fetal & Neonatal Medicine | March 16, 2021 | Volume: 35 | Issue: 20 | Pages: 4022-4027

10.1080/14767058.2020.1844656 | PMID 33722118 Get It

Guilt and Burnout in Medical Students
Greenmyer, Jacob R. , Montgomery, Michelle, Hosford, Charles C., Burd, Michael, Storandt, Michael H. , Lakpa, Koffi L. , Tiongson, Christopher, Miller, Vanessa

Mayo Clinic

Teaching and Learning in Medicine | March 16, 2021 | Volume: 34 | Issue: 1 | Pages: 69-77

10.1080/10401334.2021.1891544 | PMID 33722144 Get It